Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Your view on VRTX
Overview
What the company does, where it operates, and who runs it.
About Vertex Pharmaceuticals Incorporated
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Reshma Kewalramani FASN,
- Headquarters
- 50 Northern Avenue, Boston, MA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Reshma Kewalramani FASN,
- Headquarters
- 50 Northern Avenue, Boston, MA, US
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis.
The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation.
Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.
8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial.
The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.
; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Stock Data
Price chart, volume, and trading data.
What moved it
FRC Fair Value Algorithm
What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.
About this section
Fair value for Vertex Pharmaceuticals Incorporated from FRC's valuation model, read against the market price. VRTX last traded at $537.79, 34.3× trailing earnings — the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Vertex Pharmaceuticals Incorporated. Starting points for Vertex Pharmaceuticals Incorporated: P/E 34.3, EPS $15.68, beta 0.32 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Vertex Pharmaceuticals Incorporated. Vertex Pharmaceuticals Incorporated does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Vertex Pharmaceuticals Incorporated. Trailing twelve-month EPS for Vertex Pharmaceuticals Incorporated stands at $15.68. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.
Current price
—
live quote
Analysts' target
$574.33
average of 21 firms, last 12 months
Analyst Ratings
- Strong Buy0
- Buy20
- Hold2
- Sell1
- Strong Sell0
Earnings Estimate
| EPS | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | $4.20 | $4.64 | $18.16 | $19.95 |
| Low estimate | $3.84 | $4.13 | $17.65 | $18.13 |
| High estimate | $5.12 | $5.05 | $19.17 | $21.45 |
| No. of analysts | 14 | 5 | 17 | 17 |
| Year-ago EPS | $5.03 | $4.47 | $15.32 | — |
| Growth | -16.6% | +3.8% | +18.5% | — |
Revenue Estimate
| Revenue | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | $3.50B | $3.47B | $13.26B | $14.73B |
| Low estimate | $3.48B | $3.33B | $13.19B | $14.25B |
| High estimate | $3.52B | $3.59B | $13.29B | $15.30B |
| No. of analysts | 15 | 4 | 21 | 19 |
| Year-ago revenue | $3.19B | $2.99B | $12.00B | — |
| Growth | +9.6% | +16.2% | +10.5% | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider, Benzinga, Pulse 2.0, Investing; as of Nov 18, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Vertex Pharmaceuticals Incorporated. Vertex Pharmaceuticals Incorporated has reported as a listed company since 1991. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Peer companies
Market cap
- ALNYAlnylam Pharmaceuticals, Inc.Biotechnology$21.4B
- BBIOBridgeBio Pharma, Inc.Biotechnology$15.1B
- BEAMBeam Therapeutics Inc.Biotechnology$2.2B
- BMRNBioMarin Pharmaceutical Inc.Biotechnology$11.2B
- CRSPCRISPR Therapeutics AGBiotechnology$3.9B
- IONSIonis Pharmaceuticals, Inc.Biotechnology$4.7B
- NTLAIntellia Therapeutics, Inc.Biotechnology$1.4B
- PTCTPTC Therapeutics, Inc.Biotechnology$5.1B
More Biotechnology companies
- PTGXProtagonist Therapeutics, Inc.NASDAQ$8.1B
- PTHSPelthos Therapeutics Inc.AMEX$28M
- PTIXProtagenic Therapeutics, Inc.NASDAQ$470,654
- PTNPalatin Technologies, Inc.NASDAQ$11M
- PTX.AXPrescient Therapeutics LimitedASX
- PULMPulmatrix, Inc.NASDAQ$5M
- PVCTProvectus Biopharmaceuticals, Inc.OTC$19M
- PVLAPalvella Therapeutics, Inc.NASDAQ$2.1B
- PXMDPaxMedica, Inc. Common StockOTC$37,879
- PXXLFPoxel S.A.OTC$13M
- PYC.AXPYC Therapeutics LimitedASX
- PYPDPolyPid Ltd.NASDAQ$125M
ETFs holding Vertex Pharmaceuticals Incorporated
% of the fund
- VOOVanguard S&P 500 ETF$1.0T in assets0.22%
- VTIVanguard Total Stock Market ETF$689.2B in assets0.19%
- QQQInvesco QQQ Trust, Series 1$446.1B in assets0.64%
- IVViShares Core SP 500 ETF$852.9B in assets0.21%
- BBHVanEck Biotech ETF$536M in assets8.26%
- LSGRNatixis Loomis Sayles Focused Growth ETF$838M in assets5.25%
- HHL.TOHarvest Healthcare Leaders Income ETF$2.2B in assets4.94%
- FBTFirst Trust NYSE Arca Biotechnology Index Fund$3.0B in assets3.48%
Largest holders first, then the funds most concentrated in VRTX.
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold Vertex Pharmaceuticals Incorporated, and how their positions are changing. At a $136.35B market value, institutional positions materially move Vertex Pharmaceuticals Incorporated's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by Vertex Pharmaceuticals Incorporated executives and directors. Shares of Vertex Pharmaceuticals Incorporated have traded between $362.50 and $519.68 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
Senate Trading
U.S. Senator disclosures filed under the STOCK Act.
About this section
U.S. Senate disclosures naming Vertex Pharmaceuticals Incorporated. Vertex Pharmaceuticals Incorporated is a $136.35B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.
House Trading
U.S. Representative disclosures filed under the STOCK Act.
About this section
U.S. House of Representatives disclosures naming Vertex Pharmaceuticals Incorporated. Representatives' reported transactions in this security, shown next to the company's fundamentals.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Vertex Pharmaceuticals Incorporated. Coverage tracks Vertex Pharmaceuticals Incorporated within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Vertex Pharmaceuticals Incorporated.